Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

KG 207

Next Previous
Drug Profile

KG 207

Alternative Names: ABP-BBB; Anti-amyloid β fusion proteins; KAL-ABP; KAL-ABP-BBB; KG 207-M; KG-207

Latest Information Update: 01 Sep 2021

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator National Research Council Canada
  • Developer KalGene Pharmaceuticals; National Research Council Canada
  • Class Antibodies; Antidementias
  • Mechanism of Action Amyloid beta-protein modulators; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Alzheimer's disease

Most Recent Events

  • 05 Aug 2021 KalGene Pharmaceuticals plans a clinical trial of KG 207 for Alzheimer's disease (Parenteral)
  • 01 Aug 2021 Preclinical development in Alzheimer's disease is ongoing in Canada
  • 27 Jul 2020 Pharmacodynamics data from preclinical studies in Alzheimer's disease presented at the Alzheimer's Association International Conference (AAIC-2020)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top